Evidence map›Paper›PMID 33342555›Full record

ReviewClinical therapeutics2021

Psychotherapy and Medications for Eating Disorders: Better Together?

Deborah L Reas, Carlos M Grilo

Open access · hybridAbstract readReview
In one paragraph

Review in Clinical therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Utilising genomic association data for causal inference in anorexia nervosa.Mammalian genome : official journal of the International Mammalian Genome Society · 2025
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Binge eating disorder.Nature reviews. Disease primers · 2022
    Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Deborah L ReasRegional Department for Eating Disorders, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; Institute of Psychology, Faculty of Social Sciences, University of Oslo, Oslo, Norway. Electronic address: deborah.lynn.reas@ous-hf.no.
Carlos M GriloDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA; Department of Psychology, Yale University, New Haven, CT, USA.
University of Oslo · NOYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Treatment of Obesity and Binge Eating: Behavioral weight Loss versus Stepped CareR01DK049587 · NIDDK · YALE UNIVERSITY · PI GRILO, CARLOS M · 2002 to 2020
$8.5M
Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating DisorderR01DK112771 · NIDDK · YALE UNIVERSITY · PI GRILO, CARLOS M, MCKEE, SHERRY ANN · 2017 to 2021
$3.6M
Cognitive-Behavioral and Pharmacologic Treatment of Binge Eating DisorderR01DK114075 · NIDDK · YALE UNIVERSITY · PI GRILO, CARLOS M · 2018 to 2022
$3.6M
NCATS NIH HHS UL1 TR001863NIDDK NIH HHS R01 DK049587NIDDK NIH HHS R01 DK112771NIDDK NIH HHS R01 DK114075
6 · The paper itself

Abstract

purposeEating disorders are prevalent public health problems associated with broad psychosocial impairments and with elevated rates of psychiatric and medical comorbidities. Critical reviews of the treatment literature for eating disorders indicate that although certain specialized psychological treatments and specific medications show efficacy to varying degrees across the different eating disorders, many patients fail to derive sufficient benefit from existing treatments. This article addresses whether combining psychological and pharmacologic interventions confers any additional benefits for treating eating disorders.

methodsThis study was a critical review of randomized controlled trials (RCTs) testing combined psychological and pharmacologic treatment approaches for eating disorders with a focus on anorexia nervosa (AN), bulimia nervosa (BN), and binge-eating disorder (BED).

findingsFor AN, 3 of the 4 RCTs reported no significant advantage for combining treatments; the fourth reported a statistically significant, albeit clinically modest, advantage. For BN, 10 of the 12 RCTs reported no significant advantage for combining treatments; 2 RCTs found that combining fluoxetine with specific psychological treatments enhanced outcomes relative to medication only but not relative to the psychological treatments only. For BED, of the 12 RCTs, only 2 (both with antiseizure medications) significantly enhanced both binge-eating and weight outcomes, and only 2 (with orlistat, a weight-loss medication) enhanced weight loss but not binge-eating outcomes. IMPLICATIONS: Despite the public health significance of eating disorders, the scope of research performed on the utility of combining treatments is limited. To date, the few RCTs testing combined pharmacologic plus psychological treatments for eating disorders have yielded mostly nonsignificant findings. Future RCTs should focus on testing additive benefits of medications with relevant mechanisms of action to available effective psychological interventions. In addition, future RCTs that test additive effects should use adaptive designs, which could inform treatment algorithms to enhance outcomes among both responders and nonresponders to initial interventions.

Indexed as

AnticonvulsantsAntidepressive AgentsAnti-Obesity AgentsFeeding and Eating DisordersHumansPsychotherapyRandomized Controlled Trials as TopicAnticonvulsantsAntidepressive AgentsAnti-Obesity Agentsanorexia nervosabinge-eating disorderbulimia nervosaeating disorderspharmacotherapypsychotherapy

Identifiers

PMID33342555
PMCPMC8243253
OpenAlexW3112209917

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.